SAMSUNG PHARMACEUTICAL.CO.,Ltd.(KR:001360)
₩1,309.00+48.00 (+3.81%)
KR:001360
SAMSUNG PHARMACEUTICAL.CO.,Ltd. financials statements
₩1,309.00
At close:+48.00 (+3.81%)
Want to see KR:001360 full AI Analyst Report?
SAMSUNG PHARMACEUTICAL.CO.,Ltd. (001360) Income Statement
SAMSUNG PHARMACEUTICAL.CO.,Ltd. Income Statement
Last quarter (Q2 2026), SAMSUNG PHARMACEUTICAL.CO.,Ltd.'s total revenue was ₩9.90B, a decrease of 9.15% from the same quarter last year. In Q2, SAMSUNG PHARMACEUTICAL.CO.,Ltd.'s net income was ₩-56.65B. See SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| ₩ 46.07B | ₩ 44.29B | ₩ 51.96B | ₩ 51.83B | ₩ 54.90B | |
| ₩ 14.64B | ₩ 19.77B | ₩ 22.97B | ₩ 24.62B | ₩ 9.28B | |
| ₩ 34.10B | ₩ 34.60B | ₩ 41.01B | ₩ 38.58B | ₩ 27.42B | |
| Depreciation and Amortization | ₩ 1.44B | ₩ 2.12B | ₩ 1.91B | ₩ 3.01B | ₩ 3.20B |
| ₩ -18.06B | ₩ -11.74B | ₩ -21.69B | ₩ -21.97B | ₩ -36.46B | |
| ₩ -19.46B | ₩ -14.83B | ₩ -18.04B | ₩ -13.96B | ₩ -19.14B | |
| ₩ 31.00B | ₩ 736.92M | ₩ -5.63B | ₩ -11.13B | ₩ -21.14B | |
| ₩ 11.55B | ₩ -14.09B | ₩ -23.67B | ₩ -25.09B | ₩ -40.28B | |
| ₩ 11.55B | ₩ -14.09B | ₩ -24.81B | ₩ -25.09B | ₩ -40.28B | |
| Per Share Metrics | |||||
| Basic EPS | ₩ 122.66 | ₩ -156.21 | ₩ -333.83 | ₩ -337.30 | ₩ -547.68 |
| Diluted EPS | ₩ 122.66 | ₩ -156.21 | ₩ -333.83 | ₩ -337.30 | ₩ -547.68 |
| Weighted Average Shares Outstanding | 94.16M | 90.21M | 74.33M | 74.39M | 73.54M |
| Weighted Average Shares Outstanding (Diluted) | 94.16M | 90.21M | 74.33M | 74.39M | 73.54M |
Currency in KRW
